Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What fueled the previous growth in the pneumococcal vaccine market?

In recent times, the market size for the pneumococcal vaccine has shown a potent growth. The market, which is anticipated to increase from a worth of $8.94 billion in 2024 to $9.49 billion in 2025, enjoys a compound annual growth rate (CAGR) of 6.2%. This remarkable growth in the past is due to various factors including the discovery of streptococcus pneumoniae, public health interest, early vaccination initiatives, advancements in healthcare, and alterations in vaccine policies.

What will be the pneumococcal vaccine market size in the future?

The market size for the pneumococcal vaccine is predicted to experience significant expansion in the coming years, increasing to a value of $12.12 billion by 2029, with a compound annual growth rate (CAGR) of 6.3%. Various factors contributing to this forecasted growth include the evolution of pneumococcal strains, ongoing research and development efforts, prioritizing immunization, broadening vaccine accessibility, and an aging population. Notable trends for this period involve development of multivalent vaccines, focusing on vaccination for high-risk groups, enhancing the effectiveness of vaccines, intensifying education and awareness initiatives, and a specific focus on infant immunization.

Get your pneumococcal vaccine market report here!

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

What main drivers are fueling expansion in the pneumococcal vaccine market?

The escalating occurrence of pneumococcal infections is anticipated to drive the pneumococcal vaccine market’s expansion. Pneumococcal infections encompass any disease brought on by the bacteria known as Streptococcus pneumoniae or pneumococcus, including conditions such as pneumonia, bloodstream infections, ear, and sinus infections. The pneumococcal vaccine prompts the body to create antibodies against the pneumococcal bacteria, reducing or eliminating bacteria and toxins that cause disease, hence safeguarding children, seniors, and individuals with compromised immune systems against numerous types of pneumococcal infections. For example, the Center for Disease Control and Prevention, a US public health agency, reported an estimate of 150,000 hospital admissions due to pneumococcal pneumonia per year in January 2022, which represents up to 30% of adult-acquired pneumonia cases within the community. Thus, the rising prevalence of pneumococcal contamination fuels the pneumococcal vaccine market’s growth.

What key areas define the segmentation of the global pneumococcal vaccine market?

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

Who are the dominant players expanding their reach in the pneumococcal vaccine market?

Major companies operating in the pneumococcal vaccine market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Astellas Pharma Inc., CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, Inventprise LLC, Tergene Biotech Private Limited, PnuVax Incorporated, SK Bioscience Co Ltd

How are evolving market trends shaping pneumococcal vaccine Strategies?

Leading companies in the pneumococcal vaccine market are introducing innovative products to enhance their market profitability. For instance, in July 2023, Merck & Co Inc., an American pharmaceutical firm, introduced the V116 vaccine. This vaccine is designed to combat the eight unique serotypes of Streptococcus pneumoniae that are predominantly accountable for adult pneumococcal disease. When compared to other pneumococcal vaccines, V116 has demonstrated superior immunogenicity across various serotypes in adults, and has also elicited favourable immune responses in both individuals with no prior vaccination and those who were previously vaccinated. The U.S. Food and Drug Administration (FDA) has classified V116 as a breakthrough therapy, and it is currently undergoing Phase 3 development.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11950

Which regions are emerging as leaders in the pneumococcal vaccine market?

North America was the largest region in the pneumococcal vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Medical Waste Management Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/medical-waste-management-global-market-report

Medical Device Cleaning Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/medical-device-cleaning-global-market-report

Medical Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/medical-equipment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: